Antibodies targeting the PD-1 pathway have revolutionized the treatment management of different cancers, such as Merkel cell carcinoma (MCC), melanoma, head and neck squamous cell carcinoma (HNSCC), and non-small-cell lung cancer [18]. Here, PDCD1 is linked to non-small cell lung carcinoma.